Filtros de búsqueda

Lista de obras de Richard Baird

A Bayesian adaptive design for biomarker trials with linked treatments

artículo científico publicado en 2015

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

artículo científico publicado en 2016

A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR+/HER2- advanced breast cancer.

artículo científico publicado en 2018

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.

artículo científico publicado en 2016

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

artículo científico publicado en 2013

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial

An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients ⬇️

artículo científico publicado en 2016

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

artículo científico publicado en 2018

Antiapoptotic effect of growth factors in leukemia

artículo científico publicado en 2005

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

artículo científico publicado en 2014

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

artículo científico publicado en 2011

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

scientific article published on 16 December 2019

Clinical Development of Novel Drug-Radiotherapy Combinations

artículo científico publicado en 2018

Clinical development of new drug-radiotherapy combinations ⬇️

artículo científico publicado en 2016

Drug resistance reversal--are we getting closer?

artículo científico publicado en 2003

Enhanced detection of circulating tumor DNA by fragment size analysis

artículo científico publicado en 2018

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2015

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

artículo científico publicado en 2011

Genetic heterogeneity in breast cancer: the road to personalized medicine? ⬇️

artículo científico publicado el 18 de junio de 2013

Genomic profile of advanced breast cancer in circulating tumour DNA

artículo científico publicado en 2021

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers

artículo científico publicado en 2014

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

artículo científico publicado en 2017

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

scientific article published on 04 January 2019

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

artículo científico publicado en 2019

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.

artículo científico publicado en 2014

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

artículo científico publicado en 2016

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

artículo científico publicado en 2022

Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature.

artículo científico publicado en 2002

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

artículo científico publicado en 2020

Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia

artículo científico publicado en 2004

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

artículo científico publicado en 2013

The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials

artículo científico publicado el 1 de enero de 2012

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction

artículo científico publicado en 2010

Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications

artículo científico publicado en 2015

Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology

artículo científico publicado en 2019

Weekly paclitaxel in the treatment of recurrent ovarian cancer.

scientific article published on 03 August 2010

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda